Bioelectrical impedance can be used to predict muscle mass and hence improve estimation of glomerular filtration rate in non-diabetic patients with chronic kidney disease

Background. In this article (the second of two companion studies), we report whether bioelectrical impedance analysis (BIA) can be used to predict muscle mass in patients with chronic kidney disease (CKD), and whether using this predicted muscle mass can improve the estimation of glomerular filtrati...

Full description

Saved in:
Bibliographic Details
Published inNephrology, dialysis, transplantation Vol. 21; no. 12; pp. 3481 - 3487
Main Authors Macdonald, Jamie H., Marcora, Samuele M., Jibani, Mahdi, Roberts, Gareth, Kumwenda, Mick John, Glover, Ruth, Barron, Jeffrey, Lemmey, Andrew Bruce
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.12.2006
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background. In this article (the second of two companion studies), we report whether bioelectrical impedance analysis (BIA) can be used to predict muscle mass in patients with chronic kidney disease (CKD), and whether using this predicted muscle mass can improve the estimation of glomerular filtration rate (GFR). Methods. Seventy five non-diabetic patients with CKD (mean age ± SD, 65.1 ± 12.0 years; mean GFR 45.9 ± 28.8 ml/min/1.73 m2) underwent body composition analysis by dual energy X-ray absorptiometry to provide a criterion marker of skeletal muscle mass (appendicular lean mass, ALM). Validity of a published BIA equation to predict ALM was evaluated and a new BIA equation was generated (ALMBIA) and cross-validated by the leave-one-out procedure. Renal inulin clearance provided a criterion measure of GFR (GFRinu). The performance of the equation including ALMBIA to estimate GFRinu was compared with demographic variables as used in the modification of diet in renal disease (MDRD) equation, by determining bias, limits of agreement and accuracy. Results. The previously published BIA equation to predict ALM was not valid in these patients with CKD. In contrast, our new ALMBIA equation cross-validated successfully. Compared with the MDRD demographic variables, using ALMBIA to predict GFRinu improved estimation performance, showing reduced bias (4.3 vs 15.6 ml/min) and improved limits of agreement (41.1 vs 59.2 ml/min) and accuracy (69.7 vs 39.4% of patients’ predicted GFR did not deviate by more than 30% of GFRinu). Conclusions. ALMBIA provides a clinically obtainable and valid method to predict muscle mass in patients with CKD, and using ALMBIA improves the estimation of GFRinu. Researchers developing future GFR estimation equations should consider including ALMBIA.
Bibliography:istex:479DD59CB75CB679F7B2A5AE4A939286E29BE0DE
ark:/67375/HXZ-77HNNS4V-N
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfl432